Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK.

Adie ViljoenChristina S HoxerPierre JohansenSamuel Joseph Paul Malkin Barnaby Hunt Stephen C Bain

Published in: Diabetes, obesity & metabolism (2018)

Compared with treatment with dulaglutide, once-weekly semaglutide represents a cost-effective option for treating individuals in the UK with T2DM who are not achieving glycaemic control with metformin, projected to both improve clinical outcomes and reduce costs.

Keyphrases

climate change
cross sectional
adipose tissue
weight loss
replacement therapy